Strategies for the Improvement of Nutrition Outcomes

Volume 4, Issue 4.

In this podcast guest author Amanda Radmer Leonard, Pediatric Nutrition Practitioner, of the Johns Hopkins Children’s Center, describes approaches to the treatment of low vitamin D levels in patients with cystic fibrosis, discuss the variability of fecal elastase result during the first year of life, and summarizes the importance of tailoring nutritional interventions to specific patient and family situations.

Adherence to Chronic Inhaled Therapies

Volume 4, Issue 2.

Nonadherence to any medical regimen is common particularly among adolescents and young adults, and cystic fibrosis (CF) is no exception. There are many barriers to following the complex daily regimen that CF management requires, and researchers and clinicians have not yet found the ideal approach for counseling and supporting patients to improve and maintain their level of adherence. In this podcast Dr. Kristin Riekert, of The Johns Hopkins Adherence Research Center discusses best practices for determining which clinic patients are nonadherent and Identifies risk factors for nonadherence.

Featured Cases: Emerging Pathogens in Cystic Fibrosis

Volume 3, Issue 12.

Case studies offer opportunity to differentiate the needs of each patient when managing respiratory infections. Dr. Elliott Dasenbrook will review the prevalence of important CF organisms over the last 10 years, the impact of respiratory tract MRSA on survival, the association between a virulent strain of P. aeruginosa that can spread among patients and lung transplant or death, as well as the impact of chronic non-tuberculous Mycobacterial lung disease on lung function.

Featured Cases: The Role of Exercise and Physical Activity in Optimizing Outcomes Among Patients with CF

Volume 3, Issue 10.

Dr. Elizabeth Yen offers a clinical perspective to her review on how new research that highlights the strong positive impact of early behavioral and nutritional education and predictors of long-term response to such interventions. In this podcast she will expand on that information by discussing case scenarios.

Featured Cases: Interventions to Improve Nutrition in Patients with CF

Volume 3, Issue 8.

In this issue, Dr. Elizabeth Yen reviews new research highlighting the strong positive impact of early behavioral and nutritional education. Exploring predictors of long-term response to such interventions she discusss how body image may affect compliance with nutritional recommendations in adolescents; and, then present data describing positive outcomes with gastrostomy tube placement for supplemental enteral intake.

Featured Cases: Exacerbation Therapies

Volume 3, Issue 4.

This podcast has been developed for clinicians caring for patients with issues related to cystic fibrosis. You can also read the companion newsletter. In this edition Dr. Chris Goss will explain the use of new inhalation therapies for the treatment of cystic fibrosis, with the discussion some typical case scenarios.

Featured Cases: New Inhalation Therapies

Volume 2, Issue 12.

The eCysticFibrosis Review podcast is a clinical discussion between our November authors, Michael Boyle, MD, Elliott Dasenbrook, MD and Robert Busker, eCysticFibrosis Reviews Medical Editor. The topic is Emerging Pathogens in Cystic Fibrosis. Participants can now receive 0.5 credits per podcast after completing an online post-test via the links provided on the website page, eCysticFibrosisReview.org.

Featured Cases: State-of-the-Art Treatment for CF Lung Disease

Volume 2, Issue 10.

Clinical practice guidelines have become a regular component of health care. The Cystic Fibrosis Foundation has supported the development of several recent clinical practice guidelines to review the evidence that endorses many of the therapies currently in use.

Although numerous clinical manifestations of cystic fibrosis (CF) exist, the principal causes of disease-related morbidity and mortality are due to pancreatic insufficiency and chronic airway infection. Recommendations are now available on the assessment and treatment of nutritional disease, use of airway clearance therapies, and use of chronic medications to maintain lung health. Acute complications of CF lung disease include pulmonary exacerbations, hemoptysis, and pneumothorax; guidelines on the management of these complications are currently available as well. Finally, as newborn screening for CF has become standard in all states, we can expect that most patients will be diagnosed in the absence of symptoms. Infant care guidelines should provide primary care physicians with the information needed for appropriate assessment and treatment of newly diagnosed patients.

In this podcast recording, Dr. Patrick Flume utilizes patient cases to summarize the clinical practice guidelines for individuals with CF, to aid clinicians in improving the quality and consistency of the care they provide.

Featured Cases: Vitamin D and Bone Health

Volume 2, Issue 8.

In 2002, the CF Foundation convened a consensus conference. This consensus conference developed specific recommendations for the prevention of bone disease and the optimal supplementation of vitamin D for patients with cystic fibrosis. The original consensus guidelines did not have any actual demonstration in cystic fibrosis patients, and most of this was expert opinion. And at this time we are actually trying to test these guidelines to see if they hold true in those with cystic fibrosis. Since patients with cystic fibrosis are living longer, they are developing more complications, such as bone disease, and insuring that vitamin D supplementation is adequate and figuring out new ways to prevent bone disease is becoming more and more important for CF patients. In the discussion today, Peter Mogayzel, MD and Dianna Green, MD, of the Johns Hopkins University School of Medicine, will focus on the basis of the current vitamin D recommendation for patients with cystic fibrosis, describe the potential for success of various strategies for treatment of vitamin D insufficiency, and compare the potential benefits and risks of using bisphosphonates for the treatment of osteoporosis in patients with cystic fibrosis.